标王 热搜: 浙江  盐酸  白藜芦醇  氨基  技术  吡格列酮  吡啶  中间体  制药设备  骨科  原料药  前景广阔  武汉  中成药“避风港”或步其后尘  试剂  机构悄悄潜伏“创新药” 
 
当前位置: 首页 » 资讯 » 市场纵览 » 正文

吉利德关于抗新型冠状病毒的药物Remdesivir的声明

放大字体  缩小字体 发布日期:2020-02-04  浏览次数:144

       1月31日,吉利德发布了公司首席医学官Merdad Parsey博士针对2019新型冠状病毒(2019-nCoV)正在采取的药物研发行动的声明。

声明

       Merdad Parsey博士在声明中指出:“针对2019新型冠状病毒全球爆发这一公共卫生事件,吉利德目前正在跟全球医药卫生监管机构密切沟通合作,推进开展我们抗病毒 药物remdesivir的临床试验。吉利德愿意跟美国食品药品监督管理局(FDA)、美国疾病控制与预防中心(CDC)、美国健康与人类服务部(DHHS)、中国CDC、世界卫生组织(WHO)、 美国国家过敏和传染病研究所(NIAID)以及个人研究者和临床医师一起努力,将我们过往的抗病毒 药物研发经验和资源投入到这场战役中,帮助患者和各国机构共同抗击2019-nCoV。

       Remdesivir目前尚未在全球任何国家或地区获得批准,临床使用的安全性或有效性也尚未得到证明。但是为了响应临床医生的使用需求,以及支持部分药监机构的工作,我们已经慎重评估了提供了这个未在2019-nCoV身上取得任何数据的在研药物的风险和获益。吉利德已经为少部分需要紧急救治但缺少治疗药物的患者提供了 remdesivir。

       吉利德目前正在跟中国卫生当局密切合作,希望尽快启动一个随机、对照临床研究来确定remdesivir 能否安全有效地用于治疗2019-nCoV感染。我们也正在加快进行remdesivir抗2019-nCoV活性的实验室检测。

       尽管目前没有任何数据证明remdesivir的抗2019-nCoV活性,但是remdesivir在其他冠状病毒中显示的活性数据给了我们信心。remdesivir在体外和动物模型身上显示出了较好的抗MERS和SARS病毒的活性,这些病毒跟2019-nCoV结构相似。目前我们手上还有一些关于使用remdesivir紧急救治埃博拉病毒感染患者的临床数据可供参考。

       总之,吉利德将会快速和高效地向全球卫生机构提供支持,帮助应对这场全球范围内的严重和威胁生命的病毒爆发危机。

       remdesivir属于核苷类似物,是RNA依赖的RNA聚合酶(RdRp)抑制剂,可以通过抑制病毒核酸合成抗病毒。目前针对埃博拉病毒感染的临床研究进行到了II期阶段。

       吉利德声明原文如下:

       Gilead Sciences Statement on the Company’s ongoing Response to the 2019 Novel Coronavirus (2019-nCoV)

       Foster City, Calif., January 31, 2020 — Gilead Sciences today issued the following statement from Merdad Parsey, MD, PhD, Chief Medical Officer, Gilead Sciences:

       "Gilead is working closely with global health authorities to respond to the novel coronavirus (2019-nCoV) outbreak through the appropriate experimental use of our investigational compound remdesivir. Together with the U.S. Food and Drug Administration (FDA), the U.S. Centers for Disease Control and Prevention (CDC), the U.S. Department of Health and Human Services (DHHS), the China CDC and National Medical Product Administration (NMPA), the World Health Organization (WHO), and the U.S. National Institute of Allergies and Infectious Diseases (NIAID), and along with individual researchers and clinicians, Gilead is focused on contributing our antiviral expertise and resources to help patients and communities fighting 2019-nCoV.

       Remdesivir is not yet licensed or approved anywher globally and has not been demonstrated to be safe or effective for any use. At the request of treating physicians, and with the support of local regulatory agencies, who have weighed the risks and benefits of providing an experimental drug with no data in 2019-nCoV, Gilead has provided remdesivir for use in a small number of patients with 2019-nCoV for emergency treatment in the absence of any approved treatment options.

       Gilead is working with health authorities in China to establish a randomized, controlled trial to determine whether remdesivir can safely and effectively be used to treat 2019-nCoV. We are also expediting appropriate laboratory testing of remdesivir against 2019-nCoV samples.

       While there are no antiviral data for remdesivir that show activity against 2019-nCoV at this time, available data in other coronaviruses give us hope. Remdesivir has demonstrated in vitro and in vivo activity in animal models against the viral pathogens MERS and SARS, which are coronaviruses that are structurally similar to 2019-nCoV. There are also limited clinical data available from the emergency use of remdesivir in the treatment of patients with Ebola virus infection.

       Gilead is committed to supporting the global health community to quickly and effectively respond to serious and life-threatening viral outbreaks worldwide."

       about Gilead Sciences

       Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.

 
 
[ 资讯搜索 ]  [ 加入收藏 ]  [ 告诉好友 ]  [ 打印本文 ]  [ 关闭窗口 ]

 

 
推荐图文
推荐资讯
点击排行
 
网站首页 | 展会信息 | 欢迎扫码下载展会杂志电子版 | 帮助中心 | 国际注册与认证 | 服务指南 | 黄金板块 | 本站服务 | 联系方式 | 版权隐私 | 使用协议 | 网站地图 | 排名推广 | 广告服务 | 网站留言 | RSS订阅